AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...
Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...
AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...
Stocktwits on MSN22h
Q32 Bio Stock Plunges After Analyst Downgrades, Price-Target Slashes Over Alopecia Data: Retail Confidence DropsShares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of ...
AnaptysBio discontinues ANB032 for atopic dermatitis after a trial failure, refocusing on autoimmune assets with upcoming ...
Brittany Lancellotti, DVM, DACVD, talks about available treatment options for flea allergies, environmental allergies, and ...
H.C. Wainwright downgraded AnaptysBio (ANAB) to Neutral from Buy with a price target of $19, down from $52, after the company announced topline ...
Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study p ...
Atopic dermatitis was associated with a significantly increased bipolar disorder risk among a large population-based cohort in the US.
The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, ...
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback